Dogwood Therapeutics to sell $5 million of stock to largest shareholder Sealbond
Dogwood Therapeutics agreed on October 19, 2026 to sell 4,098,360 shares of common stock at $1.22 per share to Sealbond Limited, a subsidiary of its largest shareholder, in a private placement with expected gross proceeds of about $5 million before offering expenses. The company says the proceeds will extend its operational runway through March 2027 and fund Phase 3 preparatory work, and the issuance adds new shares that dilute existing holders.
Key points
- 4,098,360 shares of common stock at $1.22 per share, with expected gross proceeds of about $5 million before offering expenses
- Sealbond beneficially owned about 63.9% of outstanding common stock before the placement and is considered an affiliate
- Closing is expected on or before October 29, 2026; the company must file a resale registration statement by the 15th day after the October 19, 2026 agreement
- The press release says proceeds will fund Phase 3 preparatory activities and extend runway through March 2027, ahead of HAL-CINP Phase 2b topline data expected in November 2026
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 19, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.